

an advanced materials world

## **REPORT FOR SECOND QUARTER FY16**

Antaria Limited is a specialist manufacturer and supplier of materials used in the personal care and cosmetic sectors.

Antaria's two primary products are ZinClear™ a transparent zinc oxide based broad spectrum UV absorber for use in the sun care and cosmetics sector and Alusion™ an aluminium oxide pigment with applications in cosmetics products.

Antaria services its international customer-base via a global network of distributors.

**ASX: ANO** 

## **Directors**

Rade Dudurovic (Chairman) Ron Higham Lev Mizikovsky

Company Secretary
Geoff Acton

## **Quarterly Overview**

- Cash flow from operations for the December 2015 quarter was an outflow of \$317,200 compared to an outflow of \$180,986 for the December 2014 quarter, reflecting the seasonality in Antaria's sales and receipts cycle.
- The quarter showed a continuation of the positive growth in sales, particularly of the ZinClear<sup>TM</sup> range of products, resulting in strong invoicing during the quarter with receivables totalling \$1.412 million at 31 December 2015 compared with \$1.244 million at 31 December 2014. The prior year receivables balance however included a Research & Development receivable of \$0.344 million, whereas the 31 December 2015 balance does not, as the R&D claim for the 2015 financial year is still being finalised and will be lodged and accounted for in the 3<sup>rd</sup> quarter of FY16.
- The collection of the outstanding receivables balance at 31 December 2015 will benefit cash flow in the 3<sup>rd</sup> quarter of FY 16.
- Demand for the ZinClear<sup>TM</sup> range of products continues to improve due to the expansion of the distribution network and as a result of the investment in new formulations and samples. ZinClear<sup>TM</sup> revenues in the quarter grew by 46% over the December 2014 quarter.
- Alusion<sup>TM</sup> revenues, coming off a low base, were 91% higher than the December 2014 quarter, reflecting the resumption of sales to Merck KgaA. Antaria is in the early stages of a commercial dispute with Merck KgaA and this may affect sales of Alusion<sup>TM</sup> in the next 12 months.
- Antaria's cash balance at the end of the quarter was \$670,675 up from \$608,223 as at 30 June 2015.

## For further information, please contact:

Rade Dudurovic – Non Executive Chairman

Email: rade.antaria@gmail.com Mobile: +61 411 72 62 84